Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease

被引:266
作者
Reid, IR
Miller, P
Lyles, K
Fraser, W
Brown, JP
Saidi, Y
Mesenbrink, P
Su, GQ
Pak, J
Zelenakas, K
Luchi, M
Richardson, P
Hosking, D
机构
[1] Univ Auckland, Dept Med, Auckland 1, New Zealand
[2] Colorado Ctr Bone Res, Lakewood, CO USA
[3] Duke Univ, Vet Affairs Med Ctr, Durham, NC USA
[4] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England
[5] Le Ctr Hosp Univ Quebec, Ste Foy, PQ, Canada
[6] Novartis Pharma, Basel, Switzerland
[7] Novartis Pharmaceut, E Hanover, NJ USA
[8] City Hosp Nottingham, Nottingham, England
关键词
D O I
10.1056/NEJMoa044241
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The advent of bisphosphonates advanced therapy for Paget's disease, but more effective and convenient agents are needed to increase adherence. Zoledronic acid, a bisphosphonate administered as a single intravenous infusion, might meet these needs. Methods: In two identical, randomized, double-blind, actively controlled trials of 6 months' duration, we compared one 15-minute infusion of 5 mg of zoledronic acid with 60 days of oral risedronate (30 mg per day). The primary efficacy end point was the rate of therapeutic response at six months, defined as a normalization of alkaline phosphatase levels or a reduction of at least 75 percent in the total alkaline phosphatase excess. The results of the studies were pooled. Results: At six months, 96.0 percent of patients receiving zoledronic acid had a therapeutic response (169 of 176), as compared with 74.3 percent of patients receiving risedronate (127 of 171, P < 0.001). Alkaline phosphatase levels normalized in 88.6 percent of patients in the zoledronic acid group and 57.9 percent of patients in the risedronate group (P < 0.001). Zoledronic acid was associated with a shorter median time to a first therapeutic response (64 vs. 89 days, P < 0.001). Higher response rates in the zoledronic acid group were consistent across all demographic, disease-severity, and treatment-history subgroups and with changes in other bone-turnover markers. The physical-component summary score of the Medical Outcomes Study 36-item Short-Form General Health Survey, a measure of the quality of life, increased significantly from baseline at both three and six months in the zoledronic acid group and differed significantly from those in the risedronate group at three months. Pain scores improved in both groups. During post-trial follow-up (median, 190 days), 21 of 82 patients in the risedronate group had a loss of therapeutic response, as compared with 1 of 113 patients in the zoledronic acid group (P < 0.001). Conclusions: A single infusion of zoledronic acid produces more rapid, more complete, and more sustained responses in Paget's disease than does daily treatment with risedronate.
引用
收藏
页码:898 / 908
页数:11
相关论文
共 28 条
[11]  
GREEN JR, 1994, J BONE MINER RES, V9, P745
[12]   Pharmacologic profile of zoledronic acid: A highly potent inhibitor of bone resorption [J].
Green, JR ;
Rogers, MJ .
DRUG DEVELOPMENT RESEARCH, 2002, 55 (04) :210-224
[13]   PAGETS-DISEASE OF BONE - EARLY AND LATE RESPONSES TO 3 DIFFERENT MODES OF TREATMENT WITH AMINOHYDROXYPROPYLIDENE BISPHOSPHONATE (APD) [J].
HARINCK, HIJ ;
PAPAPOULOS, SE ;
BLANKSMA, HJ ;
MOOLENAAR, AJ ;
VERMEIJ, P ;
BIJVOET, OLM .
BRITISH MEDICAL JOURNAL, 1987, 295 (6609) :1301-1305
[14]   A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone [J].
Miller, PD ;
Brown, JP ;
Siris, ES ;
Hoseyni, MS ;
Axelrod, DW ;
Bekker, PJ .
AMERICAN JOURNAL OF MEDICINE, 1999, 106 (05) :513-520
[15]  
Nancollas GH, 2002, J BONE MINER RES, V17, pS368
[16]   EVALUATION OF THE EFFICACY AND SAFETY OF ORAL TILUDRONATE IN PAGETS-DISEASE OF BONE - A DOUBLE-BLIND, MULTIPLE-DOSAGE, PLACEBO-CONTROLLED STUDY [J].
REGINSTER, JY ;
COLSON, F ;
MORLOCK, G ;
COMBE, B ;
ETHGEN, D ;
GEUSENS, P .
ARTHRITIS AND RHEUMATISM, 1992, 35 (08) :967-974
[17]  
REGINSTER JY, 1993, ARTHRITIS RHEUM, V36, P134
[18]   Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial [J].
Reid, IR ;
Nicholson, GC ;
Weinstein, RS ;
Hosking, DJ ;
Cundy, T ;
Kotowicz, MA ;
Murphy, WA ;
Yeap, S ;
Dufresne, S ;
Lombardi, A ;
Musliner, TA ;
Thompson, DE ;
Yates, AJ .
AMERICAN JOURNAL OF MEDICINE, 1996, 101 (04) :341-348
[19]   Intravenous zoledronic acid in postmenopausal women with low bone mineral density. [J].
Reid, IR ;
Brown, JP ;
Burckhardt, P ;
Horowitz, Z ;
Richardson, P ;
Trechsel, U ;
Widmer, A ;
Devogelaer, J ;
Kaufman, J ;
Jaeger, P ;
Body, J ;
Meunier, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09) :653-661
[20]   Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone [J].
Reid, IR ;
Davidson, JS ;
Wattie, D ;
Wu, F ;
Lucas, J ;
Gamble, GD ;
Rutland, MD ;
Cundy, T .
BONE, 2004, 35 (01) :224-230